Protein interfaces
First Claim
Patent Images
1. A non-naturally occurring peptide of fewer than 30 amino acid residues which interacts with RAD51 Associated Protein 1′
- s (RAD51AP1′
s) binding site on human RAD51 recombinase (RAD51), wherein the non-naturally occurring peptide consists of the amino acid sequence of SEQ ID NO;
1, SEQ ID NO;
5, SEQ ID NO;
10, SEQ ID NO;
66, or SEQ ID NO;
67, wherein any of the amino acids are optionally D-amino acids.
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure provides methods to treat conditions, including cancer, using compounds that can target resistant cancer cells. The compounds can be used to sensitize resistant cancer cells or decrease the proliferation of cells. The compounds can target proteins in the DNA damage repair pathway leading to a decrease in DNA damage repair in target cells.
-
Citations
12 Claims
-
1. A non-naturally occurring peptide of fewer than 30 amino acid residues which interacts with RAD51 Associated Protein 1′
- s (RAD51AP1′
s) binding site on human RAD51 recombinase (RAD51), wherein the non-naturally occurring peptide consists of the amino acid sequence of SEQ ID NO;
1, SEQ ID NO;
5, SEQ ID NO;
10, SEQ ID NO;
66, or SEQ ID NO;
67, wherein any of the amino acids are optionally D-amino acids. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
- s (RAD51AP1′
Specification